Every Money Manager Ought to Be Aware of AbbVie's Stocks (ABBV)
In the dynamic world of pharmaceuticals, AbbVie stands out as a company that has managed to weather storms and continue its growth trajectory.
AbbVie, a spin-off from Abbott Laboratories in 2013, has been the beneficiary of market exclusivity for its products. One of its most notable products, Humira, an injectable anti-inflammation treatment, launched in 2003 and has been a significant contributor to the company's revenue. However, sales of Humira have shrunk by more than half, a trend that might concern some investors. Yet, surprisingly, AbbVie's total first-half revenue this year has seen an 8% increase.
This resilience can be attributed to AbbVie's strategic moves. The company employed additional patents to hold off biosimilar competition for Humira in the U.S. market until 2023. Moreover, the company's focus on research and development has led to the success of new treatments like Skyrizi and Rinvoq. Sales of Skyrizi bounded 69% higher year over year in the first half of 2025 to $7.8 billion, and Rinvoq racked up $3.7 billion in sales during the same period.
The success of these new treatments is a testament to AbbVie's commitment to innovation. If AbbVie can extend exclusivity periods for Rinvoq and Skyrizi as effectively as it did for Humira, shareholders could see their payments surge in the decade ahead, too.
AbbVie offers a dividend yield of 3.1% at recent prices, making it an attractive option for income-seeking investors. Over the past decade, AbbVie's quarterly dividend payout has increased by 221.6%.
Despite its impressive performance, AbbVie is not currently among the top ten recommended stocks by The Motley Fool Stock Advisor. However, it's important to note that the Stock Advisor's current top ten includes major growth leaders such as Nvidia, Microsoft, Apple, Alphabet, Amazon, Meta Platforms, Tesla, Broadcom, Oracle, and Netflix.
Investing in AbbVie can be a lucrative venture. For instance, if $1,000 was invested at the time of Netflix's recommendation on December 17, 2004, it would be worth $670,781 now. Similarly, if $1,000 was invested at the time of Nvidia's recommendation on April 15, 2005, it would be worth $1,023,752 now.
As of now, the current price of AbbVie stock is $212.34 with a market cap of $375 billion. While the company's future is uncertain, its track record of innovation and resilience suggests that it remains a strong contender in the pharmaceutical industry.
){kind=link}